SPRO

insider transactions

Spero Therapeutics, Inc. — buys & sells by directors, officers and 10% owners (SEC Form 4).

30D 90D 1Y

Net shares · 365d

-196.8K

0 buy · 196.8K sell

Net value · 365d

-$456.6K

$0 in · $456.6K out

Sentiment · 365d

Net selling

0% buying · 100% selling

Open-market trades · 365d

0 buy · 196.8K sell

Net buy / sell volume

Tap or hover the chart for daily net volume. Green = net buying, red = net selling.

All transactions

Sell·S
May 4, 26

Esther Rajavelu KEY

Chief Executive Officer, Chie…

$63.4K

25.2K sh · $2.51

Own -2%
Sell·S
Feb 6, 26

Esther Rajavelu KEY

Chief Executive Officer, Chie…

$119.9K

50.8K sh · $2.36

Own -5%
Sell·S
Feb 6, 26

Esther Rajavelu KEY

Chief Executive Officer, Chie…

$87.6K

37.1K sh · $2.36

Own -3%
Sell·S
Feb 6, 26

Timothy Keutzer

Chief Operating Officer

$44.0K

18.7K sh · $2.36

Own -2%
Sell·S
Feb 4, 26

Timothy Keutzer

Chief Operating Officer

$7.8K

3.5K sh · $2.24

Own -0%
Sell·S
Feb 3, 26

Timothy Keutzer

Chief Operating Officer

$51.8K

24.2K sh · $2.14

Own -3%
Grant·A
Feb 2, 26

Esther Rajavelu KEY

Chief Executive Officer, Chie…

$0

498.0K sh

Own New
Sell·S
Feb 2, 26

Esther Rajavelu KEY

Chief Executive Officer, Chie…

$40.6K

18.4K sh · $2.20

Own -2%
Grant·A
Feb 2, 26

Esther Rajavelu KEY

Chief Executive Officer, Chie…

$0

249.0K sh

Own +29%
Grant·A
Feb 2, 26

Timothy Keutzer

Chief Operating Officer

$0

137.0K sh

Own New
Sell·S
Feb 2, 26

Timothy Keutzer

Chief Operating Officer

$41.6K

18.9K sh · $2.20

Own -2%
Grant·A
Feb 2, 26

Timothy Keutzer

Chief Operating Officer

$0

68.0K sh

Own +9%

Date▾	Insider	Role	Type	Shares	Own Δ	Price	Value
May 4, 2026	Esther Rajavelu KEY	Chief Executive Officer, Chief Financial Officer and Chief Business Officer	Sell S	25.2K	-2%	$2.51	$63.4K
Feb 6, 2026	Esther Rajavelu KEY	Chief Executive Officer, Chief Financial Officer and Chief Business Officer	Sell S	50.8K	-5%	$2.36	$119.9K
Feb 6, 2026	Esther Rajavelu KEY	Chief Executive Officer, Chief Financial Officer and Chief Business Officer	Sell S	37.1K	-3%	$2.36	$87.6K
Feb 6, 2026	Timothy Keutzer	Chief Operating Officer	Sell S	18.7K	-2%	$2.36	$44.0K
Feb 4, 2026	Timothy Keutzer	Chief Operating Officer	Sell S	3.5K	-0%	$2.24	$7.8K
Feb 3, 2026	Timothy Keutzer	Chief Operating Officer	Sell S	24.2K	-3%	$2.14	$51.8K
Feb 2, 2026	Esther Rajavelu KEY	Chief Executive Officer, Chief Financial Officer and Chief Business Officer	Grant A	498.0K	New	—	$0
Feb 2, 2026	Esther Rajavelu KEY	Chief Executive Officer, Chief Financial Officer and Chief Business Officer	Sell S	18.4K	-2%	$2.20	$40.6K
Feb 2, 2026	Esther Rajavelu KEY	Chief Executive Officer, Chief Financial Officer and Chief Business Officer	Grant A	249.0K	+29%	—	$0
Feb 2, 2026	Timothy Keutzer	Chief Operating Officer	Grant A	137.0K	New	—	$0
Feb 2, 2026	Timothy Keutzer	Chief Operating Officer	Sell S	18.9K	-2%	$2.20	$41.6K
Feb 2, 2026	Timothy Keutzer	Chief Operating Officer	Grant A	68.0K	+9%	—	$0

About SPRO insider trading

This page tracks insider transactions for Spero Therapeutics, Inc. (SPRO) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.